Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer

SIMPLE SUMMARY: According to the Society for Immunotherapy of Cancer, primary resistance to immune checkpoint inhibitor (ICI) treatment is defined as progression of disease within 6 months of ICI treatment with patients receiving at least 6 weeks of ICI monotherapy. We evaluated factors predictive o...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yiqing, Zhao, Joseph J., Soon, Yu Yang, Kee, Adrian, Tay, Sen Hee, Aminkeng, Folefac, Ang, Yvonne, Wong, Alvin S. C., Bharwani, Lavina D., Goh, Boon Cher, Soo, Ross A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216169/
https://www.ncbi.nlm.nih.gov/pubmed/37345072
http://dx.doi.org/10.3390/cancers15102733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216169/
https://www.ncbi.nlm.nih.gov/pubmed/37345072
http://dx.doi.org/10.3390/cancers15102733

Ejemplares similares